Trade AVITA Medical, Inc. - RCEL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
AVITA Medical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 11.55 |
Open* | 11.33 |
1-Year Change* | 65.4% |
Day's Range* | 11.33 - 12.11 |
52 wk Range | 6.29-21.70 |
Average Volume (10 days) | 278.27K |
Average Volume (3 months) | 3.76M |
Market Cap | 259.85M |
P/E Ratio | -100.00K |
Shares Outstanding | 25.55M |
Revenue | 45.40M |
EPS | -1.33 |
Dividend (Yield %) | N/A |
Beta | 1.52 |
Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 4, 2023 | 11.55 | 0.44 | 3.96% | 11.11 | 11.64 | 10.85 |
Dec 1, 2023 | 11.21 | 0.72 | 6.86% | 10.49 | 11.26 | 10.48 |
Nov 30, 2023 | 10.61 | 0.07 | 0.66% | 10.54 | 10.73 | 10.48 |
Nov 29, 2023 | 10.62 | -0.13 | -1.21% | 10.75 | 10.92 | 10.56 |
Nov 28, 2023 | 10.75 | -0.06 | -0.56% | 10.81 | 10.97 | 10.69 |
Nov 27, 2023 | 10.82 | 0.31 | 2.95% | 10.51 | 10.95 | 10.38 |
Nov 24, 2023 | 10.58 | 0.21 | 2.03% | 10.37 | 10.88 | 10.28 |
Nov 22, 2023 | 10.46 | 0.28 | 2.75% | 10.18 | 10.81 | 10.15 |
Nov 21, 2023 | 10.13 | -0.69 | -6.38% | 10.82 | 11.02 | 9.99 |
Nov 20, 2023 | 12.48 | 0.16 | 1.30% | 12.32 | 12.68 | 12.12 |
Nov 17, 2023 | 12.57 | 0.10 | 0.80% | 12.47 | 12.63 | 12.19 |
Nov 16, 2023 | 12.56 | -0.11 | -0.87% | 12.67 | 12.77 | 12.03 |
Nov 15, 2023 | 12.89 | -0.41 | -3.08% | 13.30 | 13.64 | 12.86 |
Nov 14, 2023 | 13.39 | 0.70 | 5.52% | 12.69 | 13.47 | 12.53 |
Nov 13, 2023 | 12.49 | 1.47 | 13.34% | 11.02 | 12.64 | 10.98 |
Nov 10, 2023 | 11.26 | -0.93 | -7.63% | 12.19 | 12.38 | 10.75 |
Nov 9, 2023 | 9.86 | -0.38 | -3.71% | 10.24 | 10.24 | 9.78 |
Nov 8, 2023 | 10.31 | -0.08 | -0.77% | 10.39 | 10.49 | 10.14 |
Nov 7, 2023 | 10.52 | 0.11 | 1.06% | 10.41 | 10.68 | 10.25 |
Nov 6, 2023 | 10.41 | -0.24 | -2.25% | 10.65 | 10.65 | 10.30 |
AVITA Medical, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, December 5, 2023 | ||
Time (UTC) 22:00 | Country US
| Event AVITA Medical Inc Investor Webinar AVITA Medical Inc Investor WebinarForecast -Previous - |
Wednesday, February 21, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 AVITA Medical Inc Earnings Release Q4 2023 AVITA Medical Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2021 | 2020 | |
---|---|---|---|---|
Total revenue | 34.421 | 13.956 | 29.232 | 14.263 |
Revenue | 34.421 | 13.956 | 29.232 | 14.263 |
Cost of Revenue, Total | 5.666 | 1.861 | 5.723 | 2.667 |
Gross Profit | 28.755 | 12.095 | 23.509 | 11.596 |
Total Operating Expense | 61.926 | 28.379 | 55.772 | 56.942 |
Selling/General/Admin. Expenses, Total | 45.243 | 19.426 | 37.06 | 49.434 |
Research & Development | 13.857 | 7.586 | 14.818 | 8.461 |
Unusual Expense (Income) | 0.375 | 0.086 | 0.226 | 0.306 |
Other Operating Expenses, Total | -3.215 | -0.58 | -2.055 | -3.926 |
Operating Income | -27.505 | -14.423 | -26.54 | -42.679 |
Interest Income (Expense), Net Non-Operating | -0.016 | -0.017 | -0.022 | -0.033 |
Other, Net | 0.892 | 0.038 | 0.017 | 0.686 |
Net Income Before Taxes | -26.629 | -14.402 | -26.545 | -42.026 |
Net Income After Taxes | -26.665 | -14.427 | -26.583 | -42.03 |
Net Income Before Extra. Items | -26.665 | -14.427 | -26.583 | -42.03 |
Net Income | -26.665 | -14.427 | -26.583 | -42.03 |
Income Available to Common Excl. Extra. Items | -26.665 | -14.427 | -26.583 | -42.03 |
Income Available to Common Incl. Extra. Items | -26.665 | -14.427 | -26.583 | -42.03 |
Diluted Net Income | -26.665 | -14.427 | -26.583 | -42.03 |
Diluted Weighted Average Shares | 25.0002 | 24.9154 | 22.6743 | 20.291 |
Diluted EPS Excluding Extraordinary Items | -1.06659 | -0.57904 | -1.17238 | -2.07137 |
Diluted Normalized EPS | -1.05684 | -0.5768 | -1.16591 | -2.06156 |
Dividends per Share - Common Stock Primary Issue | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 11.753 | 10.55 | 9.455 | 9.092 | 8.335 |
Revenue | 11.753 | 10.55 | 9.455 | 9.092 | 8.335 |
Cost of Revenue, Total | 2.202 | 1.6 | 1.256 | 1.405 | 1.325 |
Gross Profit | 9.551 | 8.95 | 8.199 | 7.687 | 7.01 |
Total Operating Expense | 22.918 | 20.461 | 15.363 | 14.84 | 14.697 |
Selling/General/Admin. Expenses, Total | 16.162 | 14.815 | 11.663 | 10.333 | 10.763 |
Research & Development | 5.076 | 4.586 | 3.379 | 3.799 | 3.059 |
Unusual Expense (Income) | 0.002 | 0.067 | 0.091 | 0.125 | 0.061 |
Other Operating Expenses, Total | -0.53 | -0.627 | -1.026 | -0.904 | -0.551 |
Operating Income | -11.165 | -9.911 | -5.908 | -5.748 | -6.362 |
Interest Income (Expense), Net Non-Operating | -0.007 | -0.004 | -0.006 | -0.006 | -0.004 |
Other, Net | 0.801 | 0.725 | 0.585 | 0.17 | 0.109 |
Net Income Before Taxes | -10.371 | -9.19 | -5.329 | -5.584 | -6.257 |
Net Income After Taxes | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Net Income Before Extra. Items | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Net Income | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Income Available to Common Excl. Extra. Items | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Income Available to Common Incl. Extra. Items | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Diluted Net Income | -10.384 | -9.22 | -5.353 | -5.588 | -6.261 |
Diluted Weighted Average Shares | 25.2397 | 25.2021 | 25.0837 | 25.007 | 24.9712 |
Diluted EPS Excluding Extraordinary Items | -0.41141 | -0.36584 | -0.21341 | -0.22346 | -0.25073 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.41136 | -0.36411 | -0.21105 | -0.22021 | -0.24914 |
Interest Expense (Income) - Net Operating | 0.006 | 0.02 | 0.082 | 0.04 |
- Annual
- Quarterly
2022 | 2021 | 2021 | 2020 | |
---|---|---|---|---|
Total Current Assets | 87.458 | 92.132 | 121.33 | 78.387 |
Cash and Short Term Investments | 79.342 | 85.16 | 110.746 | 73.639 |
Cash | 73.639 | |||
Total Receivables, Net | 4.96 | 3.513 | 7.883 | 2.507 |
Accounts Receivable - Trade, Net | 3.935 | 3.19 | 3.467 | 2.076 |
Total Inventory | 2.125 | 2.132 | 1.647 | 1.125 |
Prepaid Expenses | 0.921 | 1.124 | 0.853 | 0.792 |
Other Current Assets, Total | 0.11 | 0.203 | 0.201 | 0.324 |
Total Assets | 98.264 | 116.015 | 125.501 | 82.462 |
Property/Plant/Equipment, Total - Net | 2.051 | 2.806 | 2.938 | 3.71 |
Property/Plant/Equipment, Total - Gross | 4.203 | 4.501 | 4.359 | 4.591 |
Accumulated Depreciation, Total | -2.152 | -1.695 | -1.421 | -0.881 |
Intangibles, Net | 0.465 | 0.443 | 0.472 | 0.364 |
Other Long Term Assets, Total | 1.36 | 0.942 | 0.761 | 0.001 |
Total Current Liabilities | 10.693 | 9.146 | 7.39 | 7.709 |
Payable/Accrued | 3.002 | 2.708 | 3.12 | 4.333 |
Accrued Expenses | 7.235 | 6.083 | 4.023 | 3.349 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.011 | |||
Other Current Liabilities, Total | 0.456 | 0.355 | 0.247 | 0.016 |
Total Liabilities | 13.524 | 11.391 | 9.846 | 10.061 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 2.831 | 2.245 | 2.456 | 2.352 |
Total Equity | 84.74 | 104.624 | 115.655 | 72.401 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 339.825 | 332.484 | 328.889 | 259.165 |
Retained Earnings (Accumulated Deficit) | -262.588 | -235.923 | -221.496 | -194.913 |
Other Equity, Total | 7.5 | 8.06 | 8.259 | 8.146 |
Total Liabilities & Shareholders’ Equity | 98.264 | 116.015 | 125.501 | 82.462 |
Total Common Shares Outstanding | 25.2084 | 24.9257 | 24.8959 | 21.4679 |
Cash & Equivalents | 18.164 | 55.511 | 110.746 | |
Short Term Investments | 61.178 | 29.649 | ||
Long Term Investments | 6.93 | 19.692 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 73.927 | 77.495 | 82.761 | 87.458 | 91.72 |
Cash and Short Term Investments | 60.118 | 66.047 | 73.451 | 79.342 | 84.172 |
Cash | |||||
Total Receivables, Net | 7.886 | 7.015 | 5.37 | 4.96 | 4.508 |
Accounts Receivable - Trade, Net | 6.159 | 6.048 | 4.825 | 3.935 | 3.699 |
Total Inventory | 4.377 | 3.058 | 2.811 | 2.125 | 1.96 |
Prepaid Expenses | 1.509 | 1.375 | 1.116 | 0.921 | 0.862 |
Other Current Assets, Total | 0.037 | 0 | 0.013 | 0.11 | 0.218 |
Total Assets | 81.014 | 86.33 | 92.622 | 98.264 | 99.932 |
Property/Plant/Equipment, Total - Net | 4.469 | 3.249 | 3.148 | 2.051 | 2.255 |
Property/Plant/Equipment, Total - Gross | 6.726 | 5.64 | 5.426 | 4.203 | 4.284 |
Accumulated Depreciation, Total | -2.257 | -2.391 | -2.278 | -2.152 | -2.029 |
Intangibles, Net | 0.459 | 0.456 | 0.461 | 0.465 | 0.449 |
Other Long Term Assets, Total | 2.159 | 2.376 | 2.063 | 1.36 | 1.496 |
Total Current Liabilities | 11.836 | 13.81 | 11.486 | 10.693 | 9.513 |
Payable/Accrued | 3.019 | 3.837 | 3.752 | 3.002 | 3.118 |
Accrued Expenses | 8.047 | 6.856 | 4.303 | 7.235 | 5.478 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 0.77 | 3.117 | 3.431 | 0.456 | 0.917 |
Total Liabilities | 18.036 | 17.683 | 15.061 | 13.524 | 11.946 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 6.2 | 3.873 | 3.575 | 2.831 | 2.433 |
Total Equity | 62.978 | 68.647 | 77.561 | 84.74 | 87.986 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 347.192 | 343.769 | 342.4 | 339.825 | 337.995 |
Retained Earnings (Accumulated Deficit) | -290.904 | -282.192 | -271.808 | -262.588 | -257.235 |
Other Equity, Total | 6.687 | 7.067 | 6.966 | 7.5 | 7.223 |
Total Liabilities & Shareholders’ Equity | 81.014 | 86.33 | 92.622 | 98.264 | 99.932 |
Total Common Shares Outstanding | 25.5507 | 25.4476 | 25.3278 | 25.2084 | 25.0309 |
Cash & Equivalents | 50.854 | 37.485 | 28.05 | 18.164 | 23.613 |
Short Term Investments | 9.264 | 28.562 | 45.401 | 61.178 | 60.559 |
Long Term Investments | 0 | 2.754 | 4.189 | 6.93 | 4.012 |
- Annual
- Quarterly
2022 | 2021 | 2021 | 2020 | |
---|---|---|---|---|
Net income/Starting Line | -26.665 | -14.427 | -26.583 | -42.03 |
Cash From Operating Activities | -19.09 | -5.501 | -25.901 | -22.747 |
Cash From Operating Activities | 0.568 | 0.33 | 0.715 | 0.465 |
Non-Cash Items | 8.203 | 3.921 | 7.323 | 17.488 |
Cash Interest Paid | 0.015 | 0.017 | 0.003 | 0.042 |
Changes in Working Capital | -1.196 | 4.675 | -7.356 | 1.33 |
Cash From Investing Activities | -19.332 | -49.682 | -1.174 | -0.847 |
Capital Expenditures | -0.452 | -0.132 | -1.174 | -0.847 |
Cash From Financing Activities | 0.9 | 0.007 | 64.049 | 77.057 |
Financing Cash Flow Items | 0 | -5.109 | -5.077 | |
Issuance (Retirement) of Stock, Net | 0.9 | 0.007 | 69.169 | 82.176 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -0.011 | -0.042 |
Foreign Exchange Effects | -0.026 | -0.059 | 0.133 | 0.003 |
Net Change in Cash | -37.548 | -55.235 | 37.107 | 53.466 |
Cash Taxes Paid | 0.017 | 0.008 | 0.042 | |
Other Investing Cash Flow Items, Total | -18.88 | -49.55 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.22 | -26.665 | -21.312 | -15.724 | -9.463 |
Cash From Operating Activities | -9.073 | -19.09 | -15.654 | -12.877 | -9.37 |
Cash From Operating Activities | 0.135 | 0.568 | 0.438 | 0.3 | 0.163 |
Non-Cash Items | 3.347 | 8.203 | 6.697 | 5.004 | 3.383 |
Cash Taxes Paid | 0.009 | 0.017 | 0.017 | 0.017 | |
Cash Interest Paid | 0.004 | 0.015 | 0.01 | 0.004 | 0 |
Changes in Working Capital | -3.335 | -1.196 | -1.477 | -2.457 | -3.453 |
Cash From Investing Activities | 18.787 | -19.332 | -16.174 | -7.845 | -22.601 |
Capital Expenditures | -0.284 | -0.452 | -0.382 | -0.278 | -0.064 |
Cash From Financing Activities | 0.171 | 0.9 | 0.001 | 0.001 | 0.001 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 0.171 | 0.9 | 0.001 | 0.001 | 0.001 |
Issuance (Retirement) of Debt, Net | 0 | 0 | |||
Foreign Exchange Effects | 0.001 | -0.026 | -0.07 | -0.052 | -0.006 |
Net Change in Cash | 9.886 | -37.548 | -31.897 | -20.773 | -31.976 |
Other Investing Cash Flow Items, Total | 19.071 | -18.88 | -15.792 | -7.567 | -22.537 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.0776 | 1548461 | 1077008 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.2972 | 1349634 | 143802 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8649 | 475157 | 225098 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.775 | 452229 | 364384 | 2023-06-30 | LOW |
Pura Vida Investments, LLC | Hedge Fund | 1.6733 | 426321 | -372601 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 1.0758 | 274097 | -61379 | 2023-06-30 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 1.0167 | 259040 | 81079 | 2023-06-30 | HIGH |
Perry (Michael S) | Individual Investor | 1.0057 | 256232 | 26689 | 2023-01-31 | LOW |
Calamos Advisors LLC | Investment Advisor/Hedge Fund | 0.8274 | 210796 | 125010 | 2023-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7656 | 195056 | 151125 | 2023-06-30 | LOW |
EAM Investors, LLC | Investment Advisor/Hedge Fund | 0.682 | 173756 | -81268 | 2023-06-30 | HIGH |
Invesco Capital Management LLC | Investment Advisor | 0.6461 | 164628 | 13134 | 2023-06-30 | LOW |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 0.6393 | 162877 | 0 | 2023-09-30 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.5948 | 151540 | 30546 | 2023-06-30 | LOW |
Russell Investments Trust Company | Investment Advisor | 0.5454 | 138969 | 138969 | 2023-06-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.4494 | 114502 | -17107 | 2023-06-30 | LOW |
GlobeFlex Capital, L.P. | Investment Advisor | 0.4483 | 114217 | -4645 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.3925 | 100000 | -112336 | 2023-06-30 | HIGH |
Assenagon Asset Management S.A. | Investment Advisor | 0.3571 | 90984 | 30137 | 2023-06-30 | HIGH |
Nuveen LLC | Pension Fund | 0.3336 | 84998 | 84998 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AVITA Medical, Inc. Company profile
About AVITA Medical Inc
AVITA Medical, Inc. is a regenerative medicine company. The Company is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. It provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AVITA Medical Inc revenues totaled $14M. Net loss totaled to $14.4M. Results are not comparable due to year end change.
Industry: | Biotechnology & Medical Research (NEC) |
28159 Avenue Stanford
Suite 220
VALENCIA
CALIFORNIA 91355
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com